StockData

Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.96−0.10 (-1.24%)

Close on Nov 17, 2026Market cap $1.31BP/E –Yield –

Novavax cash

Cash and short-term investments held at the end of each period.

Novavax's cash was $719.34M at Jun 30, 2026. For fiscal 2025 it was $735.08M, down 21.6% from the year before. Over ten years it grew 8.8% a year on average. The highest annual figure on record is $1.53B in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$735.08M-21.6%
FY2024Dec 31, 2024$938.18M+65.0%
FY2023Dec 31, 2023$568.51M-57.9%
FY2022Dec 31, 2022$1.35B-11.7%
FY2021Dec 31, 2021$1.53B+89.5%
FY2020Dec 31, 2020$806.39M+881.2%
FY2019Dec 31, 2019$82.18M-20.9%
FY2018Dec 31, 2018$103.94M-44.2%
FY2017Dec 31, 2017$186.43M-31.1%
FY2016Dec 31, 2016$270.38M-14.7%
FY2015Dec 31, 2015$316.81M+88.5%
FY2014Dec 31, 2014$168.06M+26.3%
FY2013Dec 31, 2013$133.07M+664.8%
FY2012Dec 31, 2012$17.40M+23.4%
FY2011Dec 31, 2011$14.10M+75.0%
FY2010Dec 31, 2010$8.06M-79.2%
FY2009Dec 31, 2009$38.76M+43.9%
FY2008Dec 31, 2008$26.94M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$719.34M+14.6%
Q1 FY2026Mar 31, 2026$790.33M+5.9%
Q4 FY2025Dec 31, 2025$735.08M-21.6%
Q3 FY2025Sep 30, 2025$762.89M-17.5%
Q2 FY2025Jun 30, 2025$627.54M-41.1%
Q1 FY2025Mar 31, 2025$746.62M+50.5%
Q4 FY2024Dec 31, 2024$938.18M+65.0%
Q3 FY2024Sep 30, 2024$924.49M+38.7%
Q2 FY2024Jun 30, 2024$1.06B+105.6%
Q1 FY2024Mar 31, 2024$495.94M-22.1%
Q4 FY2023Dec 31, 2023$568.51M-57.9%
Q3 FY2023Sep 30, 2023$666.36M-48.5%
Q2 FY2023Jun 30, 2023$517.94M-62.7%
Q1 FY2023Mar 31, 2023$636.94M-59.8%
Q4 FY2022Dec 31, 2022$1.35B-11.7%
Q3 FY2022Sep 30, 2022$1.29B-33.6%
Q2 FY2022Jun 30, 2022$1.39B-34.6%
Q1 FY2022Mar 31, 2022$1.58B-22.0%
Q4 FY2021Dec 31, 2021$1.53B+89.5%
Q3 FY2021Sep 30, 2021$1.95B+240.6%
Q2 FY2021Jun 30, 2021$2.12B+248.3%
Q1 FY2021Mar 31, 2021$2.03B+730.2%
Q4 FY2020Dec 31, 2020$806.39M+881.2%
Q3 FY2020Sep 30, 2020$571.60M+652.8%
Q2 FY2020Jun 30, 2020$609.48M+679.0%
Q1 FY2020Mar 31, 2020$244.67M+125.1%
Q4 FY2019Dec 31, 2019$82.18M-20.9%
Q3 FY2019Sep 30, 2019$75.93M-47.9%
Q2 FY2019Jun 30, 2019$78.24M-56.1%
Q1 FY2019Mar 31, 2019$108.68M-33.8%
Q4 FY2018Dec 31, 2018$103.94M-44.2%
Q3 FY2018Sep 30, 2018$145.65M-15.6%
Q2 FY2018Jun 30, 2018$178.20M-4.9%
Q1 FY2018Mar 31, 2018$164.20M-22.3%
Q4 FY2017Dec 31, 2017$186.43M-31.1%
Q3 FY2017Sep 30, 2017$172.60M-42.5%
Q2 FY2017Jun 30, 2017$187.30M–
Q1 FY2017Mar 31, 2017$211.20M–
Q4 FY2016Dec 31, 2016$270.38M–
Q3 FY2016Sep 30, 2016$300.28M–

More Novavax figures

See a number that looks wrong?